Latest Breaking News On - பாரத் பயோடெக் லிமிடெட் - Page 1 : vimarsana.com

Brazil has suspended the clinical studies of Bharat Biotech s COVID-19 vaccine, Covaxin following termination of the company s agreement with its partner there, the South American Country s health regulator said. Bharat Biotech on Friday announced cancellation of the MoU it signed with Precisa Medicamentos and Envixia Pharmaceuticals LL.C for its COVID-19 vaccine Covaxin for the Brazilian market. The termination of the pact comes after the deal with the Brazilian government for supply of 20 million doses of the vaccine landed in controversy and attracted investigation by authorities in that country. In The Coordination of Clinical Research at Anvisa (Copec/GGMED) determined this Friday (23/7) the precautionary suspension of clinical studies of the Covaxin vaccine in Brazil

United statesPrecisa medicamentosMedicamentos ltdaCoordination of clinical research at anvisa copecBharat biotech ltdBharat biotech limited internationalEnvixia pharmaceuticalsBharat biotechSouth american countryClinical researchPrecise comercializao de medicamentosஒன்றுபட்டது மாநிலங்களில்பாரத் பயோடெக் லிமிடெட்பாரத் பயோடெக்தெற்கு அமெரிக்கன் நாடுமருத்துவ ஆராய்ச்சி